Tag: linker

Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion

The Most Interesting Activity in ADC Development is no Longer Happening in Traditional Formats

Preclinical data from a novel, proprietary ADC technology platform being developed by ProfoundBio was being presented at the 2021 Molecular Targets and Cancer Therapeutics...

Drug-linker complexes consist of two parts: a highly toxic drug which is a small molecule that interacts with intracellular targets and functions as agents...

Authors: Tsuchikama K , An Z Title: Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Published in: Protein Cell. 2016 Oct 14. Keywords: antibody-drug conjugates; cancer;...

Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...